Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study

NCT00226798 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT00226798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00226798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study
Lead sponsor
Rambam Health Care Campus
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2003
Completion date
September 30, 2005
Enrollment
45
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma clear cell